DadFinStart your free week
DadFin › Stocks › Healthcare › MMSI

Merit Medical Systems, Inc. (MMSI) stock score

Healthcare · Medical Instruments & Supplies · United States

$87.21 ▲ +2.30% today

91.2
Dad Score, out of 100
strong

Merit Medical Systems, Inc. (MMSI) is a Medical Instruments & Supplies company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 91.2 out of 100 on the Dad Score, a strong reading that places the business ahead of 91% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #78 of 974. Its strongest axes are valuation, quality and growth; its weakest is price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Strong
Growth
Strong
Price action
Below average
Risk
Strong
Conviction
Above average
Liquidity
Above average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)35.1×
P/E (forward)18.5×
Dividend yield0.00%
Return on capital8.1%
Operating margin14.5%
Revenue growth (YoY)+11.8%
FCF yield4.0%
Net debt / EBITDA1.10×
Piotroski F-Score7 / 9
52-week change+2.5%
Market cap$5.1B
Next earningsOct 29, 2026

What subscribers see on MMSI

Start your free weekSubscriber? Open the full research →

Medical Instruments & Supplies peers

StockCompanyDad ScoreBandMarket cap
ISRGIntuitive Surgical, Inc.87.0strong$140.4B
BDXBecton, Dickinson and Company69.8middling$48.2B
MDLNMedline Inc.98.2strong$47.9B
ALCAlcon Inc.64.6middling$30.8B
RMDResMed Inc.94.3strong$30.8B
WSTWest Pharmaceutical Services, Inc.90.1strong$25.7B
SOLVSolventum Corporation71.9good$15.0B
BAXBaxter International Inc.40.5middling$12.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.